drugset / Trial / NCT02881008

Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B

NCT02881008

Phase 1/2 Completed 48 enrolled Hepatera Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

A randomized, open-label multicentre clinical trial of daily Myrcludex B versus entecavir in patients with HBeAg negative chronic hepatitis B.

Timeline

Start
2012-11-14
Primary completion
2014-10-04
Completion
2014-10-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Entecavir Small molecule 0.5 mg Oral
Subject Myrcludex B Peptide 0.5 mg Subcutaneous
Subject Myrcludex B Peptide 1 mg Subcutaneous
Subject Myrcludex B Peptide 2 mg Subcutaneous
Subject Myrcludex B Peptide 5 mg Subcutaneous
Subject Myrcludex B Peptide 10 mg Subcutaneous